Home > Project Types > CMA/CA > Puente J, Calderero V, García-Muro X, Trigo JM, Castro AJ, Martín-Escudero V, Yébenes M, Casado MA

Puente J, Calderero V, García-Muro X, Trigo JM, Castro AJ, Martín-Escudero V, Yébenes M, Casado MA

Puente J, Calderero V, García-Muro X, Trigo JM, Castro AJ, Martín-Escudero V, Yébenes M, Casado MA

 

 

Cost of managing adverse events in the treatment of first line metastasic renal cell carcinoma: bevacizumab + interferon alpha-2a compared with sunitinib in Spain
12th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Paris, France. 24-27 oct 2009